Overview

Pharmacokinetic Study of an Acute Gout Regimen

Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
This study aims to characterize the pharmacokinetic profile of colchicine after a regimen of 1.8 mg over two hours. A secondary goal is to evaluate the safety and tolerability of this regimen in healthy volunteers. To this end, all study subjects will be monitored for adverse effects throughout the entire study period.
Phase:
Phase 1
Details
Lead Sponsor:
Mutual Pharmaceutical Company, Inc.
Treatments:
Colchicine